ATE397665T1 - Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon - Google Patents

Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Info

Publication number
ATE397665T1
ATE397665T1 AT94907045T AT94907045T ATE397665T1 AT E397665 T1 ATE397665 T1 AT E397665T1 AT 94907045 T AT94907045 T AT 94907045T AT 94907045 T AT94907045 T AT 94907045T AT E397665 T1 ATE397665 T1 AT E397665T1
Authority
AT
Austria
Prior art keywords
beta
lymphotoxin
complexes
cell
alpha
Prior art date
Application number
AT94907045T
Other languages
English (en)
Inventor
Jeffrey Browning
Carl F Ware
Original Assignee
Biogen Idec Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ California filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE397665T1 publication Critical patent/ATE397665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT94907045T 1992-12-04 1993-12-02 Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon ATE397665T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99030492A 1992-12-04 1992-12-04

Publications (1)

Publication Number Publication Date
ATE397665T1 true ATE397665T1 (de) 2008-06-15

Family

ID=25536005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94907045T ATE397665T1 (de) 1992-12-04 1993-12-02 Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon

Country Status (8)

Country Link
EP (1) EP0672143B1 (de)
JP (3) JPH08507201A (de)
AT (1) ATE397665T1 (de)
AU (1) AU692146B2 (de)
CA (1) CA2150249A1 (de)
DE (1) DE69334224D1 (de)
HK (1) HK1013835A1 (de)
WO (1) WO1994013808A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
EP0809510B1 (de) * 1995-01-26 2004-06-09 Biogen, Inc. Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
EP1723967A3 (de) * 1996-10-25 2007-01-10 Biogen Idec MA, Inc. Lösliche Lymphotoxin-beta Rezeptoren, Antikörper gegen Lymphotoxin und Antikörper gegen Lymphotoxinligand als therapeutische Agenzien zur Behandlung immunogischer Krankheiten
TR199901636T2 (xx) * 1996-10-25 1999-09-21 Biogen, Inc. �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
US6998108B1 (en) * 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
SG121778A1 (en) 1998-10-09 2006-05-26 Univ Emory Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
GEP20063752B (en) 2000-10-13 2006-02-27 Biogen Inc Humanized Anti-LT-Beta-R Antibodies
WO2004002431A2 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
JP2006515750A (ja) * 2002-12-20 2006-06-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006114284A2 (en) * 2005-04-25 2006-11-02 Pluta Rechtsanwalts Gmbh AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY
SG154441A1 (en) 2006-10-20 2009-08-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501456A (ja) * 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン

Also Published As

Publication number Publication date
CA2150249A1 (en) 1994-06-23
WO1994013808A2 (en) 1994-06-23
AU6048394A (en) 1994-07-04
DE69334224D1 (de) 2008-07-17
AU692146B2 (en) 1998-06-04
WO1994013808A3 (en) 1994-08-04
JP2004135676A (ja) 2004-05-13
JP2007039464A (ja) 2007-02-15
EP0672143A1 (de) 1995-09-20
JPH08507201A (ja) 1996-08-06
EP0672143B1 (de) 2008-06-04
HK1013835A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
ATE397665T1 (de) Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
DK0536299T3 (da) Overfladekompleksbundet lymfotolksin
Shin et al. IN VIVO EXPRESSION OF TRANSFORMING GROWTH FACTOR-β1 IN HUMANS: Stimulation by Cyclosporine: 1
Diefenbach et al. Type 1 interferon (IFNα/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite
Dinarello Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β Converting Enzyme a
Powis et al. Properties and biological activities of thioredoxins
Johnson et al. Regulation of lymphokine (gamma-interferon) production by corticotropin.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
KR900700592A (ko) 용해성 티-4 유도체
Schreiber Identification of gamma-interferon as a murine macrophage-activating factor for tumor cytotoxicity
SE9002589L (sv) Neutrofil-aktiverande peptid-2
Schneider et al. The role of arginase in the immune response
EP0107498A2 (de) Synergistische Humaninterferonaktivität
De Maeyer et al. Interferons
IL91691A (en) T cell growth factor, method for the preparation thereof and pharmaceutical compositions containing the same
Takane et al. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice
Barbanti-Brodano et al. Selective killing of macrophages by amanitin-albumin conjugates
Shearer et al. Regulation of cell growth by interferon
ATE70453T1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
Sehgal et al. Interferon and its inducers
ATE352556T1 (de) Zytomodulierende lipophile peptide zur modulation der immunsystemaktivität und hemmung von entzündungen
Ortaldo et al. Augmentation of human natural killer cells with human leukocyte and human recombinant leukocyte interferon
AU3927895A (en) Lipid-splitting enzyme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties